psalexa
P&S Market Research - A market research firm

Beta-Secretase (BACE) Inhibitors Pipeline Analysis

Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: February 2017
Report Code: LS10801
Available Format:
Pages: 89

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Pipeline Overview

BACE is a cleaving enzyme of aspartyl protease with beta-secretase activity. It acts as a precursor of beta-amyloid (Aβ) protein. In Alzheimer’s disease, the Aβ protein fragments get accumulated in plaques in the brain. BACE initiates Aβ production by cleaving amyloid precursor protein (APP) to generate APPβ and C99, which is critical for the subsequent cleavage of C99 by gamma-secretase to release Aβ1-40 and Aβ1-42. Inhibition of BACE enzyme disrupts the production of toxic Aβ and forms plaque and new soluble oligomers.

Alzheimer’s disease is a common type of dementia and a fatal illness. It includes memory loss and loss of other intellectual abilities, which results in serious interference with daily life. Around 60% to 80% of dementia cases turn out to be Alzheimer’s disease. It causes problems with behavior, thinking and memory. Symptoms usually develop at a slow rate and become worse with time, causing severe interference with daily routine. The efficient inhibition of BACE is expected to stop the progression of Alzheimer’s disease. BACE inhibitors as drug candidates will block Aβ enzyme, which would prevent the buildup of beta-amyloid and may also help to reduce or halt Alzheimer’s disease.

Although significant progress has been witnessed in BACE inhibitor development, studies are still focused on BACE inhibitors with high potential, and reduced or no side effects. Also, even after promising growth in the development of BACE inhibitors, BACE therapeutics for Alzheimer’s disease treatment are still not available in the market due to the difficulty in the designing of BACE1 inhibitor drugs that can pass the blood–brain barrier.

Pipeline Analysis

As of February 2017, the BACE inhibitors pipeline comprised 15 product candidates in different stages of development.

BACE Inhibitors Pipeline Analysis

 

Competitive Landscape

Some of the key players developing BACE inhibitors pipeline are AstraZeneca plc, Eli Lilly & Company and Merck & Co and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the last stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry